[Aspirin for secondary prevention of venous thromboembolism. WARFASA: far from being conclusive]

Rev Med Interne. 2013 Feb;34(2):69-72. doi: 10.1016/j.revmed.2012.10.363. Epub 2012 Nov 13.
[Article in French]
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Aspirin / administration & dosage
  • Aspirin / adverse effects
  • Aspirin / therapeutic use*
  • Hemorrhage / epidemiology
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control
  • Humans
  • Pulmonary Embolism / chemically induced
  • Pulmonary Embolism / epidemiology
  • Pulmonary Embolism / etiology
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Risk Factors
  • Secondary Prevention / methods
  • Venous Thromboembolism / complications
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / epidemiology
  • Venous Thromboembolism / prevention & control*
  • Warfarin / administration & dosage
  • Warfarin / adverse effects
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Aspirin